_256_384.jpg){kind=logo}
News | September 16, 2022
Everstone acquires controlling stake in Softgel Healthcare
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint of the OlympiA trial, in these patients
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
Subscribe To Our Newsletter & Stay Updated
